BR112015004629A2 - polipeptídeos de clostridium difficile como vacinas - Google Patents
polipeptídeos de clostridium difficile como vacinasInfo
- Publication number
- BR112015004629A2 BR112015004629A2 BR112015004629A BR112015004629A BR112015004629A2 BR 112015004629 A2 BR112015004629 A2 BR 112015004629A2 BR 112015004629 A BR112015004629 A BR 112015004629A BR 112015004629 A BR112015004629 A BR 112015004629A BR 112015004629 A2 BR112015004629 A2 BR 112015004629A2
- Authority
- BR
- Brazil
- Prior art keywords
- vaccines
- clostridium difficile
- polypeptides
- difficile polypeptides
- difficile
- Prior art date
Links
- 241000193163 Clostridioides difficile Species 0.000 title abstract 3
- 229920001184 polypeptide Polymers 0.000 title abstract 2
- 102000004196 processed proteins & peptides Human genes 0.000 title abstract 2
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 2
- 229960005486 vaccine Drugs 0.000 title abstract 2
- 241000124008 Mammalia Species 0.000 abstract 1
- 102000039446 nucleic acids Human genes 0.000 abstract 1
- 108020004707 nucleic acids Proteins 0.000 abstract 1
- 150000007523 nucleic acids Chemical class 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Clostridium (G)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/08—Clostridium, e.g. Clostridium tetani
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
- C07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
- C07K16/1282—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Clostridium (G)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Immunology (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Pulmonology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB201216748A GB201216748D0 (en) | 2012-09-19 | 2012-09-19 | Methods of treatment |
| GB201216749A GB201216749D0 (en) | 2012-09-19 | 2012-09-19 | Antigen combinations |
| PCT/IB2013/058673 WO2014045226A1 (en) | 2012-09-19 | 2013-09-19 | Clostridium difficile polypeptides as vaccine |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112015004629A2 true BR112015004629A2 (pt) | 2017-11-21 |
Family
ID=49725168
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112015004629A BR112015004629A2 (pt) | 2012-09-19 | 2013-09-19 | polipeptídeos de clostridium difficile como vacinas |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US9932374B2 (enExample) |
| EP (1) | EP2897637A1 (enExample) |
| JP (1) | JP2015529677A (enExample) |
| KR (1) | KR20150056540A (enExample) |
| CN (1) | CN104582722A (enExample) |
| AU (1) | AU2013319821A1 (enExample) |
| BR (1) | BR112015004629A2 (enExample) |
| CA (1) | CA2882620A1 (enExample) |
| IL (1) | IL237172A0 (enExample) |
| MX (1) | MX2015002485A (enExample) |
| RU (1) | RU2015106916A (enExample) |
| SG (1) | SG11201500980WA (enExample) |
| WO (1) | WO2014045226A1 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX391236B (es) | 2011-04-22 | 2025-03-21 | Wyeth Llc | Composiciones relacionadas con una toxina de clostridium difficile mutante y sus metodos. |
| BR122016023101B1 (pt) | 2012-10-21 | 2022-03-22 | Pfizer Inc | Polipeptídeo, composição imunogênica que o compreende, bem como célula recombinante derivada de clostridium difficile |
| GB2525177A (en) * | 2014-04-14 | 2015-10-21 | New Royal Holloway & Bedford | Vaccine |
| ES2870506T3 (es) | 2015-02-19 | 2021-10-27 | Immune Biosolutions Inc | Antígeno y anticuerpo del epítopo de las toxinas a y/o b de clostridium difficile, y sus usos farmacéuticos |
| US10738338B2 (en) | 2016-10-18 | 2020-08-11 | The Research Foundation for the State University | Method and composition for biocatalytic protein-oligonucleotide conjugation and protein-oligonucleotide conjugate |
| EP3810163A1 (en) | 2018-06-19 | 2021-04-28 | GlaxoSmithKline Biologicals SA | Immunogenic composition |
| GB202205833D0 (en) | 2022-04-21 | 2022-06-08 | Glaxosmithkline Biologicals Sa | Bacteriophage |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU746859B2 (en) | 1997-06-20 | 2002-05-02 | Imperial College Of Science, Technology And Medicine | Immonogenic fragments of toxin a of clostridium difficile |
| EP1268774A2 (en) * | 2000-03-21 | 2003-01-02 | Elitra Pharmaceuticals, Inc. | Identification of essential genes in prokaryotes |
| WO2001094599A1 (en) * | 2000-06-07 | 2001-12-13 | Smittskyddsinstitutet | Gene expression cassette and its use |
| WO2002077183A2 (en) * | 2001-03-21 | 2002-10-03 | Elitra Pharmaceuticals, Inc. | Identification of essential genes in microorganisms |
| US20040029129A1 (en) * | 2001-10-25 | 2004-02-12 | Liangsu Wang | Identification of essential genes in microorganisms |
| AU2003299527A1 (en) * | 2002-06-17 | 2004-06-07 | Jimmy D. Ballard | Mutant of clostridium difficile toxin b and methods of use |
| EP2167119B1 (en) * | 2007-06-14 | 2016-08-24 | The Secretary of State for Health | Chemically modified peptides with improved immunogenicity |
| CA2714720A1 (en) * | 2008-02-28 | 2009-09-03 | 3M Innovative Properties Company | Antibodies to clostridium difficile spores and uses thereof |
| WO2011060431A2 (en) | 2009-11-16 | 2011-05-19 | University Of Maryland Baltimore | Multivalent live vector vaccine against clostridium difficile-associated disease |
| EP2519257A4 (en) * | 2009-12-02 | 2014-10-15 | Univ Tufts | ATOXIC RECOMBINANT HOLOTOXINS FROM CLOSTRIDIUM DIFFICILE AS IMMUNOGENESIS |
| SG11201402375VA (en) | 2011-12-08 | 2014-10-30 | Novartis Ag | Clostridium difficile toxin-based vaccine |
-
2013
- 2013-09-19 BR BR112015004629A patent/BR112015004629A2/pt not_active IP Right Cessation
- 2013-09-19 WO PCT/IB2013/058673 patent/WO2014045226A1/en not_active Ceased
- 2013-09-19 CA CA2882620A patent/CA2882620A1/en active Pending
- 2013-09-19 US US14/425,037 patent/US9932374B2/en active Active
- 2013-09-19 KR KR1020157005022A patent/KR20150056540A/ko not_active Withdrawn
- 2013-09-19 MX MX2015002485A patent/MX2015002485A/es unknown
- 2013-09-19 SG SG11201500980WA patent/SG11201500980WA/en unknown
- 2013-09-19 AU AU2013319821A patent/AU2013319821A1/en not_active Abandoned
- 2013-09-19 JP JP2015531683A patent/JP2015529677A/ja active Pending
- 2013-09-19 RU RU2015106916A patent/RU2015106916A/ru not_active Application Discontinuation
- 2013-09-19 CN CN201380045505.3A patent/CN104582722A/zh active Pending
- 2013-09-19 EP EP13802107.6A patent/EP2897637A1/en active Pending
-
2015
- 2015-02-10 IL IL237172A patent/IL237172A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP2015529677A (ja) | 2015-10-08 |
| EP2897637A1 (en) | 2015-07-29 |
| AU2013319821A1 (en) | 2015-02-26 |
| US9932374B2 (en) | 2018-04-03 |
| KR20150056540A (ko) | 2015-05-26 |
| MX2015002485A (es) | 2015-06-05 |
| RU2015106916A (ru) | 2016-11-10 |
| US20150315248A1 (en) | 2015-11-05 |
| SG11201500980WA (en) | 2015-04-29 |
| IL237172A0 (en) | 2015-04-30 |
| WO2014045226A1 (en) | 2014-03-27 |
| CA2882620A1 (en) | 2014-03-27 |
| CN104582722A (zh) | 2015-04-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL251194A0 (en) | Fusion proteins, recombinant bacteria, and methods for using recombinant bacteria | |
| DK2831241T3 (da) | Kunstige nukleinsyremolekyler til forbedret protein- eller peptidekspression. | |
| CR20150046A (es) | Anticuerpos anti-cd79b e inmunoconjugados | |
| EA201492221A1 (ru) | Полипептиды, имеющие активность трансгалактозилирования | |
| PT4023755T (pt) | Moléculas de ácido nucleico artificiais para uma expressão melhorada de proteína | |
| BR112015000626A2 (pt) | processos para preparação de óxido de titânio e outros produtos variados | |
| EA201791693A1 (ru) | Гетеродимерные иммуноглобулины | |
| MX2019008359A (es) | Cadena j modificada. | |
| MX384212B (es) | Metodos para cosechar cultivos de celulas de mamifero. | |
| CR20140441A (es) | Anticuerpos anti-lgr5 e inmunoconjugados | |
| UY35407A (es) | ?PROTEÍNAS DE FUSIÓN COMPRENDIENDO PORCIONES PDGF y VEGF DE UNIÓN Y MÉTODOS PARA SU USO?. | |
| EP3236772A4 (en) | Methods of purifying recombinant proteins | |
| MX362456B (es) | Anticuerpos y vacunas para utilizarse en el tratamiento de canceres por ror1 y para inhibir la metastasis. | |
| EP2900697A4 (en) | PEPTIDATED PROTEIN KNOCKDOWN | |
| MX2019007921A (es) | Nuevos agentes de union a ha. | |
| BR112015004629A2 (pt) | polipeptídeos de clostridium difficile como vacinas | |
| DK3143138T3 (da) | Betinget aktive biologiske proteiner | |
| IN2014DN05885A (enExample) | ||
| CY1117214T1 (el) | Συνθεση για ελεγχομενη διεγερση των ωοθηκων | |
| IL251571A0 (en) | Variable proteins comprising the cry1da1 amino acid sequence are activated by lepidopteran | |
| GT201800102A (es) | Polipéptidos que inhiben cd4ol | |
| IL250646A0 (en) | A process for conjugating a peptide or protein with a reagent containing a leaving group that includes a peg moiety | |
| BR112017009792A2 (pt) | anticorpos anti-pdgf-b e métodos de uso | |
| MX378905B (es) | Pestivirus. | |
| LT3191514T (lt) | Ligandai, sustiprinantys gonadotropinų biologinį aktyvumą |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] |
Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI |
|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 6A ANUIDADE. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2532 DE 16-07-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |